-DOCSTART- -X- O
Severe -X- _ O
acute -X- _ O
respiratory -X- _ O
syndrome -X- _ O
( -X- _ O
SARS -X- _ O
) -X- _ O
is -X- _ O
an -X- _ O
emerging -X- _ O
infectious -X- _ O
disease -X- _ O
caused -X- _ O
by -X- _ O
a -X- _ O
novel -X- _ O
coronavirus -X- _ O
( -X- _ O
SARS-CoV -X- _ O
) -X- _ O
. -X- _ O
The -X- _ O
binding -X- _ O
of -X- _ O
SARS-CoV -X- _ B-Patient
spike -X- _ I-Patient
( -X- _ I-Patient
S -X- _ I-Patient
) -X- _ I-Patient
protein -X- _ I-Patient
to -X- _ I-Patient
cellular -X- _ I-Patient
angiotensin-converting -X- _ I-Patient
enzyme -X- _ I-Patient
2 -X- _ I-Patient
( -X- _ I-Patient
ACE2 -X- _ I-Patient
) -X- _ I-Patient
is -X- _ O
the -X- _ O
first -X- _ O
step -X- _ O
in -X- _ O
SARS-CoV -X- _ O
infection. -X- _ O
Therefore -X- _ O
, -X- _ O
we -X- _ O
assayed -X- _ O
the -X- _ O
inhibitory -X- _ O
effects -X- _ O
of -X- _ O
small -X- _ B-Intervention
peptides -X- _ I-Intervention
derived -X- _ O
from -X- _ O
S -X- _ O
protein -X- _ O
on -X- _ O
the -X- _ O
binding -X- _ O
of -X- _ O
S -X- _ O
protein -X- _ O
to -X- _ O
ACE2 -X- _ O
and -X- _ O
on -X- _ O
the -X- _ O
S-protein-pseudotyped -X- _ O
retrovirus -X- _ O
infectivity. -X- _ O
SP-4 -X- _ B-Intervention
( -X- _ I-Intervention
residues -X- _ I-Intervention
192–203 -X- _ I-Intervention
) -X- _ I-Intervention
, -X- _ I-Intervention
SP-8 -X- _ I-Intervention
( -X- _ I-Intervention
residues -X- _ I-Intervention
483–494 -X- _ I-Intervention
) -X- _ I-Intervention
, -X- _ I-Intervention
and -X- _ I-Intervention
SP-10 -X- _ I-Intervention
( -X- _ I-Intervention
residues -X- _ I-Intervention
668–679 -X- _ I-Intervention
) -X- _ I-Intervention
significantly -X- _ B-Outcome
blocked -X- _ I-Outcome
the -X- _ I-Outcome
interaction -X- _ I-Outcome
between -X- _ I-Outcome
S -X- _ I-Outcome
protein -X- _ I-Outcome
and -X- _ I-Outcome
ACE2 -X- _ I-Outcome
by -X- _ I-Outcome
biotinylated -X- _ I-Outcome
enzyme-linked -X- _ I-Outcome
immunosorbent -X- _ I-Outcome
assay -X- _ I-Outcome
, -X- _ I-Outcome
with -X- _ I-Outcome
IC50 -X- _ I-Outcome
values -X- _ I-Outcome
of -X- _ I-Outcome
4.30±2.18 -X- _ I-Outcome
, -X- _ I-Outcome
6.99±0.71 -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
1.88±0.52nmol -X- _ I-Outcome
, -X- _ I-Outcome
respectively. -X- _ I-Outcome
Peptide -X- _ O
scanning -X- _ O
suggested -X- _ O
the -X- _ O
region -X- _ B-Outcome
spanning -X- _ I-Outcome
residues -X- _ I-Outcome
660–683 -X- _ I-Outcome
might -X- _ I-Outcome
act -X- _ I-Outcome
as -X- _ I-Outcome
a -X- _ I-Outcome
receptor-binding -X- _ I-Outcome
domain. -X- _ I-Outcome
SP-10 -X- _ B-Outcome
blocked -X- _ I-Outcome
both -X- _ I-Outcome
binding -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
S -X- _ I-Outcome
protein -X- _ I-Outcome
and -X- _ I-Outcome
infectivity -X- _ I-Outcome
of -X- _ I-Outcome
S -X- _ I-Outcome
protein-pseudotyped -X- _ I-Outcome
retrovirus -X- _ I-Outcome
to -X- _ I-Outcome
Vero -X- _ I-Outcome
E6 -X- _ I-Outcome
cells. -X- _ I-Outcome
In -X- _ O
conclusion -X- _ O
, -X- _ O
this -X- _ O
is -X- _ O
the -X- _ O
first -X- _ O
report -X- _ O
of -X- _ O
small -X- _ O
peptides -X- _ O
designed -X- _ O
to -X- _ O
disrupt -X- _ O
the -X- _ O
binding -X- _ O
of -X- _ O
SARS-CoV -X- _ O
S -X- _ O
protein -X- _ O
to -X- _ O
ACE2. -X- _ O
Our -X- _ O
findings -X- _ O
suggest -X- _ O
that -X- _ O
SP-10 -X- _ O
may -X- _ O
be -X- _ O
developed -X- _ O
as -X- _ O
an -X- _ O
anti-SARS-CoV -X- _ O
agent -X- _ O
for -X- _ O
the -X- _ O
treatment -X- _ O
of -X- _ O
SARS-CoV -X- _ O
infection -X- _ O
. -X- _ O

